

AMENDMENT

IN THE CLAIMS:

Please cancel claims 19 and 20 as follows:

10. (Previously presented) A composition comprising adenoviral particles, a buffer solution that maintains the pH of said composition between 8.0 and 9.6, and glycerol, wherein said buffer solution does not contain added divalent metal cations or alkali metal cations.
11. (Previously presented) The composition according to claim 10, wherein said composition is frozen.
12. (Previously presented) The composition according to claim 10, wherein the buffer solution maintains the pH of said composition between 8.4 and 8.8.
13. (Previously presented) The composition according to claim 12, wherein the buffer solution maintains the pH of said composition at 8.4.
14. (Previously presented) The composition according to claim 10, wherein the buffer solution comprises: (a) Tris or lysine and an acid chosen from a strong acid or a weak acid; or (b) Hepes and a strong base.
15. (Previously presented) The composition according to claim 14, wherein the buffer solution comprises Tris/HCl, lysine/HCl, Tris/maleic acid, Tris/malic acid, Tris/acetic acid, or Hepes/sodium hydroxide.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

16. (Previously presented) The composition according to claim 10, further comprising an adjuvant.
17. (Previously presented) The composition according to claim 16, wherein the adjuvant is a polymer, sugar, or alcohol.
18. (Previously presented) The composition according to claim 17, wherein the adjuvant is a polymer chosen from a polyethylene glycol, a pluronic, or a polysorbate.
19. (Canceled)
20. (Canceled)
21. (Previously presented) A method of preserving adenoviruses in a composition comprising:
preparing a purified sample of adenoviral particles; and
combining said purified sample of adenoviral particles with glycerol and a buffer solution that maintains the pH of the resulting composition between 8.0 and 9.6, wherein said buffer solution does not contain added divalent metal cations or alkali metal cations.
22. (Previously presented) The method according to claim 21, further comprising freezing said composition.
23. (Previously presented) The method according to claim 22, further comprising thawing said frozen composition.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

24. (Previously presented) A composition comprising adenoviral particles, a buffer solution and glycerol, wherein the buffer solution does not contain added divalent metal cations or alkali metal cations, and wherein the buffer solution is at a pH sufficient to preserve adenovirus in stable form.
25. (Previously presented) A method of preserving adenoviruses in a composition at a temperature of up to about 20°C, comprising:
 - preparing a purified sample of adenoviral particles;
 - combining the purified sample of adenoviral particles with glycerol and a buffer solution wherein the buffer solution does not contain added divalent metal cations or alkali metal cations; and
 - storing the adenovirus composition at a temperature of up to about 20°C.
26. (Previously presented) The method according to claim 25, wherein the adenovirus composition is stored at a temperature of about 4°C.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com